What does this research mean for the field?

Implementation of the updated BCID2 multiplex PCR panel significantly reduces the time to effective antimicrobial therapy in gram-negative bloodstream infections, particularly for resistant organisms, compared to the previous BCID panel. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical impact of implementing the updated BIOFIRE Blood Culture Identification 2 (BCID2) multiplex PCR panel on time to effective antibiotic therapy in patients with gram-negative bloodstream infections.

September 2, 2026Journal of Clinical MicrobiologyOpen Access

Evaluation of time to antibiotic therapy after implementation of an updated rapid diagnostic test for gram-negative bacteremia

View Full Paper

Ask AI

Bookmark

To evaluate the clinical impact of implementing the updated BIOFIRE Blood Culture Identification 2 (BCID2) multiplex PCR panel on time to effective antibiotic therapy in patients with gram-negative bloodstream infections.
Single-center, retrospective, quasi-experimental study conducted from March 1, 2022, to March 1, 2024.
Included 180 adult patients (n=90 in the BCID group and n=90 in the BCID2 group) with gram-negative bloodstream infections who received at least 48 hours of antibiotic therapy.
Primary endpoint was time to effective antimicrobial therapy; secondary endpoints evaluated time to appropriate therapy, 30-day mortality, and hospital length of stay.
Median time to effective antimicrobial therapy was significantly shorter in the BCID2 group compared to the BCID group (1 vs 4 h, P = 0.004), whereas overall time to appropriate therapy did not differ significantly (25 vs 49 h, P = 0.627).
In the ESBL subgroup, BCID2 significantly shortened both median time to effective therapy (0.5 vs 3 h, P = 0.006) and median time to appropriate therapy (16 vs 44 h, P = 0.016).
No statistically significant differences occurred between BCID and BCID2 groups in 30-day mortality (6.7% vs 8.9%, P = 0.756) or hospital length of stay (10 vs 14 days, P = 0.134).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Quasi-experimental study demonstrates faster time to effective antibiotic therapy with updated rapid PCR in gram-negative bacteremia, highlighting the value of expanded resistance detection.

Cite This Study

Hussein et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2c5c562ede874ec70ae https://doi.org/10.1128/jcm.00328-26

View Full Paper

Ask AI

Bookmark

Implication

Quasi-experimental study demonstrates faster time to effective antibiotic therapy with updated rapid PCR in gram-negative bacteremia, highlighting the value of expanded resistance detection.

Evaluation of time to antibiotic therapy after implementation of an updated rapid diagnostic test for gram-negative bacteremia

Key Points

Discussion

Implication

Cite This Study

Evaluation of time to antibiotic therapy after implementation of an updated rapid diagnostic test for gram-negative bacteremia

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading